Summary
Introduction
Antisoma is a development stage biotechnology company focused on the development of novel anticancer drugs. The Company has built a diversified product pipeline based on in-licensing and acquisitions that target a variety of tumors by different mechanisms.
Scope
Contains corporate strategy, value chain presence and SWOT Analysis Provides detailed business description, segment analysis, 5-year financial trends, key products and key competitors Includes information on suppliers/ partners, shareholding structure and key employees with biographies
Highlights
Antisoma's product pipeline is built on in licensing or acquiring product candidates from other biopharmaceutical companies. The company licensed its lead candidate was licensed from Cancer Research Technology. The second product candidate is AS1409 was licensed from Merck. The company also obtained exclusive license of AS1402 from Cancer Research Technology. AS1411 was obtained from the acquisition of Aptamera in 2005. In addition, Antisoma collaborated with Argenta Discovery, a pharmaceutical R&D group, to develop improved molecules for Antisoma's programme of telomere targeting agents (TTAs). Antisoma's total revenues decreased at a CAGR of 7% from $4 million to $3 million during 2002-2006. While the company has no market products, the only revenue source was through upfront and development payments from Roche for licensing ASA404 (AS1404), AS1402 (R1550) and R1549.
Reasons to Purchase
Access all the important information and analysis on the company in a single report Understand company's strengths, weaknesses, opportunities and threats along with business strategy and value chain Gain access to company's adjusted five year financial data along with key ratios and market capitalization .
|
